| Vol. 14.15 – 29 April, 2022 |
| |
|
|
| Scientists suggested that the peripheral nervous system may have directly interacted with diseased arteries. Widespread neuroimmune cardiovascular interfaces arose in mice and human atherosclerosis-diseased adventitia segments showed expanded axon networks. [Nature] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers showed that maladaptive bone marrow-mediated trained innate immunity underlied inflammatory comorbidities, as exemplified by the periodontitis-arthritis axis. [Cell] |
|
|
|
| The authors developed an MG1 peptide and RVG29 peptide engineered nanoerythrocyte that could reprogram microglia from classical M1 toward alternative M2 by inducing heme oxygenase-1, stimulating Notch1/Hes1/Stat3 signaling, and further inhibiting NF-κB p65 translocation. [Advanced Materials] |
|
|
|
| Scientists investigated transcriptional and epigenetic changes after acute, periodic and persistent IL-2 receptor signaling in mouse peripheral regulatory T cells in vivo using IL-2 or the long-acting IL-2-based biologic mouse IL-2–CD25. [Nature Immunology] |
|
|
|
| Investigators used mouse models of DOCA+salt treatment and adoptive transfer of CD8+ T cells (CD8T) from hypertensive animals to normotensive animals in in vivo studies. [Circulation Research] |
|
|
|
| Researchers reported that the LynB splice variant of the Src-family kinase Lyn exerted a dominant immunosuppressive function in vivo, whereas the LynA isoform was uniquely required to restrain autoimmunity in female mice. [Science Immunology] |
|
|
|
| Scientists used an in vitro differentiation system and human skin–grafted mice to study memory T cell generation from circulating human memory T cell subsets. [Science Immunology] |
|
|
|
| The authors showed that negative elongation factor (NELF), an RNA polymerase II pausing factor, cooperated with T cell factor 1 in T cell responses to cancer. [Nature Communications] |
|
|
|
| Investigators showed that the strength of T cell receptor signaling controlled the requirement for interleukin-2 (IL-2) signals to form a pool of memory CD8+ T cells that competitively re-expanded upon secondary antigen encounter. [Nature Communications] |
|
|
|
| Scientists found that combined oral FAK inhibitor plus function-blocking TIGIT antibody immunotherapy reduced tumor burden, prolonged mouse survival, and led to immune cell activation and tertiary lymphoid structure formation, hallmarks of an antitumor immune response. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Using single-cell transcriptomic analysis, researchers found that several CD4+ T-cell subsets were present in the intestines of colitic mice, including an interferon (IFN)-γ-producing subset. [Cellular & Molecular Immunology] |
|
|
|
| Investigators showed that expression of Vav1-Myo1f, a recurrent peripheral T cell lymphoma-associated VAV1 fusion, induces oncogenic transformation of CD4+ T cells. [Cell Reports] |
|
|
|
| The authors characterized islet antigen-specific T cells in non-obese diabetic mice lacking all three interferon receptor genes. [Cell Reports] |
|
|
|
|
| Investigators discuss the current understanding of the multiple roles of TCF-1 in T cell development and function and their mechanistic underpinnings. [Nature Immunology] |
|
|
|
| The authors discuss how extracellular, de novo synthesized and membrane lipids orchestrate T cell biology and describe the roles of lipids as regulators of intracellular signaling at the levels of transcriptional, epigenetic and post-translational regulation in T cells. [Nature Chemical Biology] |
|
|
|
| Scientists discuss the interaction between macrophages and ferroptosis concerning three metabolisms and integrate the application of certain relationship in curing diseases, mostly cancer. [Cell Death & Disease] |
|
|
|
|
| Applied Molecular Transport, Inc. announced positive top-line Phase II results from the FILLMORE monotherapy trial for AMT-101 in patients with chronic pouchitis, an orphan indication with significant unmet medical need and no current FDA-approved therapies. [Applied Molecular Transport, Inc.] |
|
|
|
|
| May 30 – June 1, 2022 Brisbane, Queensland, Australia |
|
|
|
|
|
| New York University College of Dentistry – New York, New York, United States |
|
|
|
| The Pirbright Institute – Pirbright, England, United Kingdom |
|
|
|
| Francis Crick Institute – London, England, United Kingdom |
|
|
|
| Uppsala University – Uppsala, Sweden |
|
|
|
| Fred Hutchinson Cancer Center – Seattle, Washington, United States |
|
|
|
|